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2.1 ABSTRACT 
 
Aim:  
The aims of this audit were:  
To determine the proportion of hyperthyroid patients receiving I-131 therapy in 
whom treatment with a single fixed dose was successful, as defined by the 
achievement of euthyroidism or hypothyroidism 6-months after the therapy; 
To identify patients in whom treatment was not successful and a second dose 
needed;  
 
And, if possible, to establish the factors associated with treatment failure. 
 
Methods:  
A single observer reviewed the records of all patients who received I-131 therapy for 
hyperthyroidism between 23rd April 2010 and 23rd November 2017 in conjunction with 
their pre and post treatment thyroid function tests. Results of their thyroid ultrasound 
were retrieved and documented. The images of their Tc-99m sodium pertechnetate 
thyroid scans were also retrieved and reprocessed.  
Results:  
The records of 409 patients treated between April 2010 and November 2017 were 
retrieved. 223 (63%) patients were referred by the endocrine clinic at Groote Schuur 
hospital (GSH. Of the 409 patients, 56 (14%) patients that were excluded because their 
post therapy records were not available for analysis. 
 
Majority of our patients were females 310 (88%). Patients between the ages of 15 and 
45 years are more likely to present with Grave’s disease while those aged more than 
45 years presented with toxic multinodular gland (p=0.000). Patients that presented 
between the ages of 15 and 45 years are more likely to have moderately increased 
pretreatment FT4 (12-51 mmol/L) (p=0.002). We administered a radioiodine therapy 
dose of 456.6±54.8 MBq (Mean ± SD) to these 409 patients. Among the 353 patients, 
with complete records, 314(89%) achieved cure at some stage after receiving one 
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dose of RAI; 239(76%) achieving cure ≤ 6 months of therapy and 75(24%) patients after 
6 months.  
 
In our audit the patients who failed to achieve cure following the first RAI therapy 
appeared to be younger (median(interquartile range) age 39(16), p= 0.03), have 
severe hyperthyroidism as demonstrated by higher pre-treatment FT4 
(median(interquartile range) 27 pmol/L(30.6), p= 0.05) and high pertechnetate uptake 
(median(interquartile range) uptake 9.9%(14), p= 0.002) on thyroid scintigraphy.  
 
CONCLUSION  
Our audit showed RAI therapy was found to be successful in 68% of patients at 6 
month and 89% at a year.  A second therapy with radioactive iodine would be 
indicated in 32% of patients, as these patients have not achieved cure at 6 months. 
Patients presenting with severe thyrotoxicity are likely to require more than one RAI 
therapy. Due to major deficiencies in referral, record keeping and follow up, other 
factors responsible for treatment were not be able to be evaluated.  
 
Based on these findings, suggested areas for further research are: should patients with 
severe hyperthyroidism be considered for pretreatment with antithyroid medication 
prior to RAI; would a one year follow up after radioiodine therapy be considered 
before second RAI.   
 
Now that the deficiencies in our current practice have been identified and suggestions 
put forward to address these deficiencies, a follow up audit would be needed.  
 
Key words: Hyperthyroidism, I-131 (Radioiodine) therapy, Effectiveness. 
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1.0 RESEARCH PROTOCOL 
 
This research protocol was submitted to and approved by the Faculty of Health Sciences, 
University of Cape Town before the commencement of the study.  
Research topic – Efficacy of single fixed dose of radioiodine (I-131) therapy in patients 
with hyperthyroidism at Nuclear Medicine Department of Groote Schuur Hospital. 
1.1 Background 
Since 2011, Nuclear Medicine Department of Groote Schuur Hospital (GSH) has been 
conducting radioiodine therapy (RAI) for patients referred with hyperthyroidism, 
from Endocrine Unit of the hospital and other sites.  
The Department has used the single fixed dose method of RAI administration in the 
management of hyperthyroidism, so the objective of this research project is to 
retrospectively review the therapy and assess its effectiveness. 
1.2 Literature Review 
Introduction 
Since 2011, Nuclear Medicine Department of Groote Schuur Hospital (GSH) has 
been conducting radioiodine therapy (RAI) for patients referred with 
hyperthyroidism from Endocrine Unit of the hospital and other sites.  
The objective of this research project is to retrospectively review the therapy and 
assess its effectiveness. 
Objective of Literature Review 
The Department has used the single fixed dose method of RAI administration in the 
management of hyperthyroidism, so this literature review focuses on the impacts 
of this approach on the outcome of the treatment and predictors of its failure. 
 Types of Studies 
• Studies on the use of RAI in hyperthyroidism 
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Inclusion criteria 
• Studies in which the outcome of a single fixed dose of radioiodine in 
hyperthyroidism was evaluated,  
• Studies that compare the effectiveness of single dose and calculated method 
of determining dose were also included in the review.  
Exclusion criteria 
• Use of radioiodine in the treatment of cancer, 
 
Literature search strategy 
An Internet search of PubMed was undertaken.  The first key phrase searched was 
“the use of single dose of RAI in treatment of hyperthyroidism” on the 29 August 
2017. Out of the fifteen articles retrieved only ten were considered to meet the 
criteria and included in the review. The five that were excluded were: one full text 
article in Spanish, three studies that did not use RAI and addressing only a second 
dose.  
Another phrase used was “incidence of hypothyroidism following radioiodine 
treatment”. Of the twenty seven articles retrieved twenty three were excluded. 
Seven used long term follow up not applicable to this review of our practice, the full 
text of two articles was not accessible, three studies used the calculated method for 
deciding the I-131 dose, four articles did not use I-131, two studies focused on 
cancer therapy, one paper dealt with hyperthyroidism in children, three papers were 
on hypothyroidism.  
Of the 28-studies and their references comparison of fixed and calculated dose of 
RAI in the management of hyperthyroidism was evaluated in the literature review. 
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Literature 
Definitions 
Hyperthyroidism is a clinical condition associated with high synthesis and secretion 
of thyroid hormone(s) by the thyroid gland. Thyrotoxicosis which is often confused 
with the former is a clinical state that is the result of high thyroid hormone action in 
tissues due to inappropriately high blood levels of thyroid hormones (1).  
Symptoms and Signs of hyperthyroidism 
Effects of hyperthyroidism are wide as it influences virtually all tissues and organ 
system; the cardiovascular system effects are one of the most deleterious(2, 3). 
Symptoms of overt thyrotoxicosis include heat intolerance, palpitations, anxiety, 
fatigue, weight loss and irregular menstruation in females(4). On examination there 
may be tremor, tachycardia, lid lag, and warm moist skin(2).  
Diagnosis of Hyperthyroidism 
Diagnosis of hyperthyroidism is made with low serum TSH level. Hyperthyroidism is 
generally considered as overt or subclinical, depending on the biochemical severity. 
Overt hyperthyroidism is diagnosed in patients with low serum level of thyroid 
stimulating hormone (TSH) and elevated serum triiodothyronine (T3) and/or free 
thyroxine (free T4) levels, while subclinical hyperthyroidism is defined as low level 
serum TSH with normal levels of T3 and free T4.  
In order to differentiate the causes of hyperthyroidism, several investigations are 
available: measurement of thyroid receptor antibodies (TRab), determination of 
radioactive iodine uptake (RAIU), ultrasonography and I-123 or Tc-99m 
pertechnetate thyroid scan (1). 
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Types of Hyperthyroidism 
Hyperthyroidism may be due to wide variety of causes among which thyroiditis, 
Grave’s disease (GD) and toxic nodular goiter are the most common(3).  
Of the many benign disease conditions that cause hyperthyroidism, only 3 are treated 
with radioiodine (RAI) therapy: 
• Grave’s disease (GD): an autoimmune disease with homogeneous increased 
uptake on RAI or Tc-99m pertechnetate scans. 
• Toxic multinodular goiter: has heterogeneous increased uptake by the thyroid 
gland with or without hot nodules.  
• Toxic adenoma presents as hot nodule with suppression of the uptake in the 
remaining thyroid gland.  
Scintigraphy distinguishes these conditions from those with high serum levels of 
thyroid hormones and near- absent uptake in pertechnetate scan;  
• Thyroiditis 
• Factitious hyperthyroidism 
• Struma ovarii 
Treatment 
According to the American Thyroid Association (ATA) guideline on the management 
of hyperthyroidism, all patients diagnosed with symptomatic thyrotoxicosis should be 
placed on β-blockade, especially elderly patients, patients with a resting heart rate of  
>90beats/min and patients with coexistent cardiovascular disease(1). 
Three forms of treatment of the thyroid diseases associated with hyperthyroidism are 
available: surgery is done to patients with large goiter (≥80g) and obstructive 
symptoms, mostly toxic multinodular goiters(2). Kang et al(5) in 2002 reported that 
96% of patients with toxic multinodular goiter had their hyperthyroidism resolved one 
month after thyroidectomy. Anti thyroid drugs (ATD’s) is the second option; they are 
very effective in controlling symptoms of thyrotoxicosis. However Jia Liu et al (6) 
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reported in March 2017 that ATD’s are associated with a high recurrence rate of up to 
59% in Grave’s disease patients treated with ATD’s only. The third option is RAI. 
Radioiodine 
Iodine-131 (I-131) has been successfully used in treatment of thyrotoxicosis for more 
than 70 years and is now recommended as a first line treatment in some forms of 
thyrotoxicosis (1). Its history dates back to 1936 when Saul Hertz asked Karl Compton 
during a lecture presentation by the latter at Harvard Medical School, if radioactive 
iodine could be produced. This question triggered a series of work that led to the 
production of I-131, the radionuclide that is used today. I-131 was first used in a 
human to treat hyperthyroidism on October 12, 1941 by Hamilton and Beck(7). 
I-131 emits b-particles as well as g-rays and has a half-life of approximately 8 days. 
This isotope is very suitable in a therapeutic setting because its effect on the 
thyrocytes is primarily the result of the b-particle radiation, which has a path length 
of 1–2 mm. The g-rays are important in imaging and in radiation protection(8). 
Currently, I-131 is available as sodium iodide in gelatine capsules and as solutions for 
oral application or intravenous injection. The thyroid follicular cells take up iodine. 
Retention of iodine in the cells depends on the metabolic activity of the cells. 
Approximately 30% of Iodine gets trapped by the thyroid gland and 70% directly 
excreted in the urine(8). After oral administration of I-131 capsule, the maximum 
blood level is reached approximately 3 hours later. Thyroid is the critical organ for 
iodine. Radioiodine is 90% excreted via urine (50% is excreted by 24 hours) and the 
remaining 10% via sweat and faeces(9). 
Cayir et al(10) in their recent systemic review concluded that I-131 is safe and cost 
effective alternative to surgery and medical therapy while Chao et al(11) in 2015 
reported that recurrence is less likely in patients that receive I-131 when compared 
with patients that receive ATD’s. 
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The adverse effects that have been associated with the use of I-131 are either due to 
a transient exacerbation of hyperthyroid symptoms from radiation thyroiditis or extra 
thyroidal such as worsening of thyroid orbitopathy, sialadenitis, immunogenic effects, 
teratogenicity and carcinogenicity (8, 12).  
Radioiodine therapy is contraindicated in pregnancy, lactation, patients with a thyroid 
nodule suspicious of thyroid cancer and patients that are unable to comply with 
radiation safety guidelines (1). 
Radioiodine Administration 
The 2016 ATA Guidelines recommend the following patient preparation prior to 
administration of I-131 therapy: 
• Medical therapy of any comorbid disease should be optimized before I-131 
therapy. 
• β-adrenergic blockade medication and anti thyroid drugs (ATD) should be 
considered even in asymptomatic patients if they are at increased risk for 
complications due to worsening of hyperthyroidism (i.e., elderly patients and 
patients with comorbidities). The advantage of pretreatment with ATD’s is that 
they deplete thyroid hormone stores and reduce the likely-hood of post 
radioiodine treatment associated transient worsening of hyperthyroidism. 
However, they are known to be radio protective and it has been reported that 
ATD’s lower the uptake of I-131 by the thyroid gland and reduce its effective 
half-life, consequently reducing the effectiveness of the I-131 therapy(13-16). 
This can be compensated by discontinuation of carbimazole for 2 days or 
prophylthiouracil (PTU) for 2-3 weeks before giving dose of I-131(17-20). 
• Patients who were on ATDs before being prepared for the therapeutic dose of 
I-131 and those at increased risk of worsening hyperthyroidism should resume 
ATDs 3 to 7 days after I-131 therapy. 
Radioiodine Dose 
Over the last 30 to 40 years, the aim of RAI therapy has shifted from making the 
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patients euthyroid to completely ablating the thyroid gland (1).  The reason for this 
was to shorten the time during which the patient is managed for the disease process 
and prevent recurrence. This must be considered when interpreting papers, 
particularly those on the effectiveness of RAI therapy.  At Groote Schuur Hospital we 
use the single administration of 370 MBq with the aim to render the patient 
hypothyroid. In South Africa we may only administer a maximum dose of 370 MBq on 
an outpatient basis(21), as this is the dose most likely to result in radiation 
measurement of 25USv/hr at 1 meter. 
Low dose (<370MBq) of I-131 is associated with prolonged hyperthyroid state with its 
attendant morbidity and increased risks of cardiovascular complications(22) while a 
high dose (≥	370	MBq)	renders patients hypothyroid more quickly(23-25). Nordyke et 
al in their study to find an adequate fixed dose of I-131 for thyrotoxicosis in 605 
patients reported that the optimal fixed dose for cure was 370MBq(26). Both Royal 
College of Physicians(27)and ATA (1) in their guidelines recommend dose of 370 MBq.  
Another method of estimating the dose is through calculating the activity to be 
administered. Many formulae have been used but the most common are the Marinelli 
and modified Marinelli formulae. These formulae all have measured Iodine kinetics in 
the thyroid gland with RAIU. Other parameters used are estimated weight of the gland 
and target radiation dose to the gland.  
Weight x MBq (desired)         
           Uptake 
 
Weight is estimated by palpation and is defined as x-times normal. 
The desired dose used is based on the diagnosis i.e 5.5MBq for Grave’s disease and 
7.5MBq for toxic multinodular goiter. 
Uptake of iodine by the thyroid is measured 24h after an I-131 tracer dose using a 
collimated scintillation probe and compared with a neck phantom. These are 
corrected for background radiation. 
Uptake is calculated = Patient’s count – background   x 100 
                                           Phantom counts- background 
 16 
  
There is no difference in the therapeutic outcome associated with this method and it 
increases complexity in the patients’ management and cost while fixed dose is more 
effective(10, 28-31).  
1.3.2 Effectiveness of single fixed dose 
During follow up, the effectiveness of radioiodine therapy is assessed with the history, 
clinical examination and serum levels of TSH and FT4. It has been recommended that 
interpretation of serum TSH within the first two months of receiving I-131 be done 
with caution as TSH may remain suppressed for a long period after hyperthyroidism 
resolves(1). Follow up of patients starts at six weeks post therapy in our center and 
treatment success is defined as the attainment of euthyroidism or hypothyroidism 
within a period of three to six months post therapy. This is in-line with the ATA 
recommendations and is well documented in India(32), the Middle east(33) and 
Europe(34, 35). 
The reports on the effectiveness of a single fixed dose I-131 and the factors that affect 
outcome differ. Many reports describe equal success rates with the lower dose (<370 
MBq) and a higher dose (³370 MBq) of I-131(36-43). Allahabadia et al(44) and 
Schneider et al(45) in retrospective studies reported that there were statistically 
significant different cure rates between patients who received single doses of 185 
MBq and those that received 370 MBq (P<0.0001). Boelaert et al compared the 
effectiveness of 370 MBq with 592 MBq in 1240 patients. They found a much higher 
success rate in patients that received 592 MBq than 370 MBq group(46).  
Patient age is another factor considered to affect the outcome of I-131 therapy. 
Jensen et al(47) in a retrospective study compared the treatment outcome of two 
groups of patients: Group 1 with a mean age of 44± 12 years and group 2 with a mean 
age of 51.3 ± 15.1. They concluded that there is no association between the patient 
age and the outcome of the therapy as the cure rate in group 1 was 60% and in group 
2 was 59%. Schneider et al(45) and Aktas et al(48)showed that elderly patients are 
more likely to respond well with radioiodine than younger patients in univariate 
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analysis but Schneider et al reported this association was lost when multivariate 
analysis was conducted. Again, there are many reports of no association between 
I-131 success rate with patient’s age(28, 39, 49-51), among which is a large population 
size retrospective study conducted by Metso et al at Tampere University Hospital in 
Finland(42). Boelaert et al reports female patients had a statistically significant higher 
success rate compared to males(46). In other studies (26, 31, 42, 52) females tended 
to have higher success rate but the association was not statistically significant.  And 
other studies showed no association between the patients’ gender and treatment 
outcome (31, 41, 45, 47, 50, 53, 54). 
While some studies(42, 45, 49) reported that patients with low 24-hour I-123 uptake 
prior to administration are likely to have a lower cure rate, others reported no 
association between the two(28, 39, 50, 55, 56). 
Thyroid goiter is associated with poor outcome of I-131 therapy(52) although another 
study reported no association was found(39). This controversy could be explained by 
the fact that these studies did not use an objective measurement of the thyroid size; 
they only used palpation. 
The effect of higher pretreatment free T4 levels and Tc-99m uptake on the outcome 
of I-131 therapy is still controversial. Maha et al conducted a retrospective study to 
assess the efficacy of 370 MBq and 555 MBq doses of I-131 in Grave’s disease patients, 
they found that higher pretreatment free T4 and Tc-99m uptake were not associated 
with treatment failure. Alexander et al(57) and Allahabadia et al(52) reports 
otherwise. 
Another factor that has been reported to affect the outcome of I-131 therapy for 
hyperthyroidism is thyroid receptor antibody level in serum(58). Michelangeli et al 
(59) in 1995 measured the level of thyroid stimulating antibody (TSab), thyroid 
blocking antibody (TBab) and TSH binding inhibitory immunoglobulin (TBII) in patients 
with Grave’s disease before and after I-131 therapy and reported that patients who 
develop early hypothyroidism following I-131 therapy had higher basal TBab level. 
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Some drugs have been known to alter the effectiveness of radioiodine therapy; one is 
lithium(60). Vangu and Hammond in their simple randomized experimental cohort 
study found that patients that receive lithium with I-131 are more likely to achieve 
successful therapy(61, 62). The effect of steroids has also been studied. They are 
routinely used to prevent exacerbation of thyroid associated orbithopathy and are 
known to inhibit the secretion of TSH, decrease peripheral deiodination, decrease the 
serum level of thyroxine binding globulin and enhance urinary iodine clearance(63). 
The anti-inflammatory effect with enhanced urinary excretion of Iodine could possibly 
decrease the effectiveness of radioiodine therapy. However studies have shown that 
outcome of I-131 therapy is not likely to be influenced by prior administration of 
steroids. This may be because the steroid dose is not sufficient(47, 64). The effect of 
smoking on RAI therapy is still unsettled, majority reporting it has no effect(31, 54, 
65).  
Radioactive iodine therapy for hyperthyroidism at Groote Schuur Hospital dates back 
to 1965 when I-131 therapy was conducted by the Department of Radiation Oncology 
in conjunction with Endocrine clinic(66). There has not been review of the 
effectiveness of the therapy since 2011 when the Nuclear Medicine department took 
over. This project proposal becomes important to evaluate the success and failure of 
the current protocol of I-131 therapy. 
Research questions 
1. In what percentage of patients receiving I-131 therapy was the treatment 
successful? 
2. A) In which patients was the treatment not successful and a second dose 
needed?  
B) What factors could be responsible for the treatment failure? 
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Research Methodology 
Design 
Patients’ treatment records from the commencement of Iodine therapy (April 2010) 
will be retrieved from the Departmental benign therapy records. Missing records may 
necessitate retrieval of patient’s main hospital folder. Tc-99m pertechnetate scans will 
be reviewed; laboratory results and thyroid ultrasound (if available) of patients who 
were treated in Nuclear Medicine Department of Groote Schuur Hospital will be 
retrieved retrospectively.  
Data collection 
Patients’ folder number, gender, age, address, history and examination details will be 
recorded in a data sheet (Appendix 1). Tc-99m pertechnetate thyroid scan will be 
retrieved and reprocessed on the Hermes processing station. The researcher will read 
laboratory results on the National Health Laboratory Service (NHLS) track and the 
ultrasound reports on the GSH isite enterprise. 
Data processing 
Both quantitative and qualitative data will be entered in the excel spreadsheet. Excel 
and SPSS package will be used for the descriptive statistical tests. 
Research limitations 
Only the researcher will be involved in interpreting the Nuclear Medicine scan in 
addition to the retrospective nature of the study. 
Ethical Issues 
Patients’ details used in the study will only be available to individuals involved in the 
study and will be properly stored; As prescribed by Helsinki declaration(67), no 
patients’ detail will be used in the final report and patients’ confidentiality will be 
maintained throughout the study.  
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2.1 ABSTRACT 
 
Aim:  
The aims of this audit were:  
To determine the proportion of hyperthyroid patients receiving I-131 therapy in 
whom treatment with a single fixed dose was successful, as defined by the 
achievement of euthyroidism or hypothyroidism 6-months after the therapy; 
To identify patients in whom treatment was not successful and a second dose 
needed;  
 
And, if possible, to establish the factors associated with treatment failure. 
 
Methods:  
A single observer reviewed the records of all patients who received I-131 therapy for 
hyperthyroidism between 23rd April 2010 and 23rd November 2017 in conjunction with 
their pre and post treatment thyroid function tests. Results of their thyroid ultrasound 
were retrieved and documented. The images of their Tc-99m sodium pertechnetate 
thyroid scans were also retrieved and reprocessed.  
Results:  
The records of 409 patients treated between April 2010 and November 2017 were 
retrieved. 223 (63%) patients were referred by the endocrine clinic at Groote Schuur 
hospital (GSH. Of the 409 patients, 56 (14%) patients that were excluded because their 
post therapy records were not available for analysis. 
 
Majority of our patients were females 310 (88%). Patients between the ages of 15 and 
45 years are more likely to present with Grave’s disease while those aged more than 
45 years presented with toxic multinodular gland (p=0.000). Patients that presented 
between the ages of 15 and 45 years are more likely to have moderately increased 
pretreatment FT4 (12-51 mmol/L) (p=0.002). We administered a radioiodine therapy 
dose of 456.6±54.8 MBq (Mean ± SD) to these 409 patients. Among the 353 patients, 
with complete records, 314(89%) achieved cure at some stage after receiving one 
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dose of RAI; 239(76%) achieving cure ≤ 6 months of therapy and 75(24%) patients after 
6 months.  
 
In our audit the patients who failed to achieve cure following the first RAI therapy 
appeared to be younger (median(interquartile range) age 39(16), p= 0.03), have 
severe hyperthyroidism as demonstrated by higher pre-treatment FT4 
(median(interquartile range) 27 pmol/L(30.6), p= 0.05) and high pertechnetate uptake 
(median(interquartile range) uptake 9.9%(14), p= 0.002) on thyroid scintigraphy.  
 
CONCLUSION  
Our audit showed RAI therapy was found to be successful in 68% of patients at 6 
month and 89% at a year.  A second therapy with radioactive iodine would be 
indicated in 32% of patients, as these patients have not achieved cure at 6 months. 
Patients presenting with severe thyrotoxicity are likely to require more than one RAI 
therapy. Due to major deficiencies in referral, record keeping and follow up, other 
factors responsible for treatment were not be able to be evaluated.  
 
Based on these findings, suggested areas for further research are: should patients with 
severe hyperthyroidism be considered for pretreatment with antithyroid medication 
prior to RAI; would a one year follow up after radioiodine therapy be considered 
before second RAI.   
 
Now that the deficiencies in our current practice have been identified and suggestions 
put forward to address these deficiencies, a follow up audit would be needed.  
 
Key words: Hyperthyroidism, I-131 (Radioiodine) therapy, Effectiveness. 
 
  
   
 
 29 
2.2 MAIN MANUSCRIPT 
Introduction 
Iodine-131 (I-131) has been successfully used in the treatment of hyperthyroidism for 
more than 70 years and is now recommended as a first line treatment in some forms 
of thyrotoxicosis (1). Its history dates to 1936 when Saul Hertz asked Karl Compton, 
during a lecture presentation by the latter at Harvard Medical School, if radioactive 
iodine could be produced. This question triggered a series of work that led to the 
production of I-131, the radionuclide that is used today. I-131 was first used in a 
human to treat hyperthyroidism on October 12, 1941 by Hamilton and Beck(2). 
Cayir et al(3); in their recent systemic review on the use of radioiodine in benign 
thyroid disease, concluded that treatment of hyperthyroidism with I-131 is a safe and 
cost effective alternative to surgery and medical therapy.  Chao et al(4) reported in 
2015 that the recurrence of hyperthyroidism is less likely in patients that receive I-131 
when compared with patients that receive antithyroid drugs (ATD’s). There are two 
approaches to the administration of radioiodine, a fixed dose or a calculated dose. 
There is no difference in the therapeutic outcomes however with the calculated dose 
more investigations are needed with   increasing complexity and cost (3, 5-8).  
The adverse effects that have been associated with the use of I-131 are either due to 
a transient exacerbation of hyperthyroid symptoms from radiation thyroiditis or extra 
thyroidal such as worsening of thyroid orbithopathy, sialadenitis, immunogenic 
effects, teratogenicity and carcinogenicity (9, 10). Radioiodine therapy is 
contraindicated in pregnancy, lactation, patients with a thyroid nodule suspicious of 
thyroid cancer and patients that are unable to comply with radiation safety guidelines 
(1). 
Radioactive iodine therapy for hyperthyroidism at GSH dates back to 1965 when I-131 
therapy was conducted by the Department of Radiation Oncology in conjunction with 
Endocrine clinic(11). Since 2011, the Nuclear Medicine Department of GSH has been 
conducting radioiodine therapy (RAI) for patients referred with hyperthyroidism by 
the Endocrine Unit of the hospital and other sites. There has not been a review of the 
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effectiveness of the therapy. The Nuclear Medicine department has used the single 
fixed dose method of RAI administration in the management of hyperthyroidism. 
The aims of this audit were:  
• To determine the proportion of hyperthyroid patients receiving I-131 therapy 
in whom treatment with a single fixed dose was successful, as defined by 
achievement of euthyroidism or hypothyroidism 6-months after the therapy; 
• To identify patients in whom treatment was not successful and a second dose 
needed;  
• And, if possible, to establish the factors associated with treatment failure. 
Methods 
All the Nuclear Medicine Department patient treatment records of Iodine therapy 
between April 2010 and November 2017 were retrieved. A separate Departmental 
attendance register was checked to identify patients who received I-131. Patients 
receiving treatment for thyroid cancer were excluded.  
The patient treatment records included, for each visit, the history, physical 
examination findings, results of investigations, diagnosis and therapy.   GSH patients 
who required I-131 therapy were discussed telephonically by the registrars of Nuclear 
Medicine and Endocrine Units.  There was not a formal referral letter for every patient. 
Our policy during the course of this study (April 2010 to November 2017) was to 
withdraw antithyroid medication five days prior to I-131 administration and schedule 
a first follow up visit in Endocrine clinic six weeks post I-131 administration.   
The protocol included a Tc-99m sodium pertechnetate thyroid scan to confirm uptake 
by the thyroid gland and thyroid ultrasound to characterize any suspicious areas 
before the therapy dose was given.  
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The thyroid scintigraphy images were acquired using Tc-99m sodium pertechnetate. 
Adults received approximately 100MBq Tc-99m sodium pertechnetate while 
paediatric doses were calculated based on the EANM dosage card (version 1.5.2008). 
Either a Siemens ecam signature series dual head gamma camera or a Symbia hybrid 
SPECT-CT system (Siemens Medical Solutions) was used to acquire static images using 
low energy high resolution (LEHR) and pinhole collimators for 10 minutes duration 
each. The raw data images were stored in the Departmental electronic archive Hermes 
processing station (Hermes Gold P5 type, version 4.15).   
The dose of I-131 was administered orally in the therapy room in the Nuclear Medicine 
Department after contraindications had been excluded and thyroid scintigraphy had 
confirmed uptake by the thyroid. The patient was allowed to leave the department 
when the level of radiation being emitted has dropped to a safe level (£ 25µSv/hr at 
1 meter according to South African legislation).  
Patient follow up was done by the respective referring physician. The first thyroid 
function test was done within 8-weeks after radioiodine administration and 
subsequently at 2 to 3 monthly intervals.   
Three consecutive thyroid function tests were used to identify patients who had 
achieved cure (euthyroid or hypothyroid status 6 months after therapy).  
Data collection 
Data collection took place between January and July 2018. The available information 
on each patient was recorded on a data sheet (Appendix 1); the folder number, 
gender, date of birth, address, history, Tc-99m sodium pertechnetate thyroid scan 
results (after the raw data had been retrieved from Nuclear Medicine Division’s 
electronic image archive (GSH Hermes archive) and reprocessed), thyroid ultrasound 
report (retrieved from the GSH Isite enterprise) and all the laboratory results on the 
National Health Laboratory Service (NHLS) track. Items not present in the treatment 
records and results which could not be traced were considered to be missing data and 
recorded on the data collection sheets as NR (not recorded).  
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 Data processing 
Data was entered into an Excel spreadsheet. Excel (Microsoft Office 2011) and SPSS 
package version 25, 2017 were used for the descriptive statistical tests. Baseline data 
is presented as frequencies or median and interquartile range if not normally 
distributed. c2 – test and Mann- Whitney U- test (where appropriate) were used for 
statistical analysis.  
Two limitations were identified: The first being the retrospective nature of the study 
and the second only the researcher was involved in interpreting the Nuclear Medicine 
scans.  
The Human Research Ethics Committee of the Faculty of Health Sciences, University 
of Cape Town, duly approved the study. HREC REF: 072/2018. 
 
RESULTS 
 
The records of 409 patients treated between April 2010 and November 2017 were 
retrieved. From our records 223 (63.%) patients were referred by the endocrine clinic 
of Groote Schuur Hospital. Many important components of the patients’ history and 
examination were not available for evaluation.  That included; whether the patients 
had hypertension, cardiac disease, diabetes and eye signs which were not recorded in 
69%, 95.2%, 88.7% and 70.3% respectively as shown in table 1. In addition, important 
information that is reported in the literature to affect the outcome of RAI therapy was 
also not available for evaluation. Examples of these variables are duration of 
treatment with carbimazole, findings on neck palpation and ultrasound findings, as 
shown in table 2.  
 
Of the 409 patients that received a single fixed dose of I-131 therapy within the period 
under review, 56 (14%) were excluded, among this, 6 patients were referred from 
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private and their post therapy blood results were not available while the remaining 50 
patients were lost to follow up leaving 353(86%) for analysis.  
 
Majority of our patients are females 310 (88%). For analysis, patients were divided 
into those less than 15 years, 15 to 45 years and more than 45 years at presentation. 
Patients between the ages of 15 to 45 years are more likely to present with Grave’s 
disease than older patients (p=0.000) and are more likely to have moderately high 
pretreatment FT4 of between 12 to 51mmol/L(p=0.002). While the older patients (>45 
years) are more likely to present with TMG (p=0.000). The rest of the demographic, 
clinical and laboratory characteristics of our patients at presentation are summarized 
in table 1 and 3.  
 
Of these 353 patients, 314(89%) patients achieved cure at some stage after receiving 
one dose of RAI. Of the 314 patients, 239(76%) achieved cure ≤ 6 months of therapy 
and 75(24%) patients after 6 months. We administered a radioiodine therapy dose of 
456.6±54.8 MBq (Mean ± SD) to all 353 patients.  
 
Of the 39 patients that remained hyperthyroid one year after receiving their first 
therapy dose, 22 patients were referred back and received a second dose of RAI 
therapy. Of these 22 patients, 20 patients achieved cure after the second therapy 
dose.  The remaining 2 were still hyperthyroid at 7 and 9 months respectively after the 
second RAI therapy dose.   
 
Our audit suggested that, among the patients that were adequately followed up, those 
that failed the first RAI therapy were younger (median age 39(interquartile range 16) 
p= 0.03), had more marked hyperthyroidism as demonstrated by higher pre-
treatment FT4 (median(interquartile range) 27 pmol/L(30.6), p= 0.05)and high 
pertechnetate uptake (median(interquartile range) uptake 9.9%(14), p= 0.002)on 
thyroid scintigraphy. 
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DISCUSSION 
 
Our audit showed major deficiencies in referral, record keeping and follow up. In many 
of our patients there were several clinical variables that were not available. The 
practice during the time covered by the audit was to discuss the referral of the patient 
between endocrinology and nuclear medicine telephonically. This may have resulted 
in information not being elicited from the referring physicians or not documented 
during the telephonic conversation. Examples are a history of hypertension, diabetes, 
cardiac diseases and the duration of carbimazole treatment. In addition, clinical and 
laboratory findings were not completed by the nuclear physician during the evaluation 
at the time of the therapy. This included thyroid size (enlarged/not enlarged); thyroid 
consistency on palpation and whether a thyroid ultrasound had been done. There are 
reports that these variables affect the outcome of radioiodine therapy (9, 12, 13). This 
meant we had insufficient data to evaluate the effect of clinical and biochemical 
findings on the outcome of the therapy.  
 
In addition there were 56 (14%) patients that were lost to follow up. This group had 
to be excluded in our analysis. 
 
This audit has been invaluable in identifying the weaknesses in current practice. The 
findings of this audit are being used to improve referral systems, record keeping and 
follow up of these patients. With regards to the referral system, a template of the 
pertinent information should be available. This should include the date of diagnosis, 
previous medical history, duration of treatment with anti-thyroid drugs and baseline 
and summary of the laboratory tests done. This should be available to both referring 
physicians and nuclear medicine physicians. When the patient is seen prior to the 
administration of RAI by the nuclear physicians a more detailed user-friendly 
treatment form may be helpful. The data sheet used for this study could serve as a 
good template. 
 
The mean dose of 457 MBq used was within the range of 370MBq to 555MBq as 
recommended by ATA guideline(1) and resulted in a euthyroid or hypothyroid state in 
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68% of the 353 patients with adequate follow up at 6 months and 89% at a year. Our 
findings at 6 months are comparable to those reported by Allahabadia et al, Leslie et 
al and Alexander et al (14-16). This result is higher than the 63% reported by Yau et 
al(17) and the same as 68% in those who received only RAI in Hammond et al(18).  It 
is important to take note of the fact that  follow up was lost in 14% of our patients. 
These findings do however raise the question, is 3 months too early to perform a 
second radioactive iodine therapy or should this decision be delayed for 1 year. This 
need further research to validate this finding. 
 
Our audit suggests that failure of RAI is more likely in patients that are younger than 
39 years with severe hyperthyroidism, as demonstrated by higher pre-treatment FT4 
and higher pertechnetate uptake.  This is consistent with reports in the literature (7, 
19-21). The failure of radioiodine activity in patients with severe hyperthyroidism may 
be attributed to the high I-131 turnover in the thyroid tissue with a shorter transit 
time as described recently by Zhang et al in China(22). This finding suggests delaying 
RAI therapy in severely thyrotoxic patients and using anti thyroid medication until 
thyrotoxicosis is moderately controlled. However the delay should not be so long as 
to cause radio resistance, as reported by Shivaprasad et al(23) 
 
Our data showed the majority of the patients had Grave’s disease (53%). This could 
possibly explain why there was no association between the  type of hyperthyroidism 
and RAI failure, as has been previously reported (12, 24, 25).  
 
Some of the limitations of this study is its retrospective design. Retrospective studies 
are prone to misclassification bias. The studies are subject to confounding factors. 
With a retrospective study, one cannot determine causation, only association and has 
been the case in this study, key statistics cannot be measured. It is also difficult to 
assess temporal relationship.   
 
An additional limitation is the large number of missing data that did not allow 
comprehensive analysis. The result been factors which are reported to influence the 
treatment outcome could net be evaluated in this study. 
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CONCLUSION  
 
In this study, the RAI therapy of patients with hyperthyroidism that received RAI 
therapy in Nuclear Medicine Department at Groote Schuur Hospital from April 2010 
to November 2017 was audited.   
 
In patients who were followed up, RAI therapy was found to be successful in 68% of 
patients at 6 month and 89% at a year.  A second therapy with radioactive iodine 
would be indicated in 32% of patients, as these patients have not achieved cure at 6 
months. Patients presenting with severe thyrotoxicity are likely to require more than 
one RAI therapy. Due to major deficiencies in referral, record keeping and follow up, 
other factors responsible for treatment were not be able to be evaluated.  
 
Based on these findings, suggested areas for further research are: should patients with 
severe hyperthyroidism be considered for pretreatment with antithyroid medication 
prior to RAI; would a one year follow up after radioiodine therapy be considered 
before second RAI.   
 
Now that the deficiencies in our current practice have been identified and suggestions 
put forward to address these deficiencies, a follow up audit would be needed.  
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3.0 Appendices: 
Tables 
Table 1: Distribution of patients’ clinical information. 
  Number of 
patients (%) 
Not recorded  
(%) 
Gender (n) 
 
Females 
Males 
310 (88) 
43 (12) 
0 
Age (n) 
 
<15 years 
15-45 years 
>45 years 
5 (1.4) 
148 (41.9) 
200 (56.7) 
0 
Hypertension (n) Yes  109 (30.9) 244 (69.1) 
Cardiac diseases (n) Atrial fibrillation  
Angina  
8 (2.3) 
 
9 (2.5) 
336 (95.2) 
Diabetes (n) 
 
Type-1 
Type-2 
4 (1.0) 
36 (10) 
313 (88.7) 
Eye symptoms (n) 
 
Yes 
No 
55(15.6) 
283 (80.2) 
15 (4.0) 
Smoking (n) 
 
Yes 
No 
115 (32.6) 
208 (80.2) 
14 (4.0) 
 
Action tremors (n) Yes 
No 
67 (19) 
258 (73.1) 
28 (7.9) 
 
Pretreatment heart rate (n) 
 
<60 b/min 
61-80 b/min 
>80 b/min 
35 (9.9) 
167 (47.3) 
143 (40.5) 
8 (2.3) 
Pretreatment TSH (n)  <2.7 mIU/l 
0.27-4.2 mIU/l 
> 4.2 mIU/l 
312 (88.4) 
29 (8.2) 
6 (1.7) 
6 (1.7) 
Pretreatment FT4 (n)  <12pmol/L 
12-51 pmol/L 
>51 pmol/L 
34 (9.6) 
280 (79.3) 
28 (7.9) 
11 (3.1) 
Pretreatment Pertechnetate 
thyroid uptake scan (n) 
Yes 
No 
343 (97.2) 
7 (2.0) 
3 (0.8) 
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Table 2. Showing distribution of missing variables. 
Clinical variables Recorded (%) Not recorded 
Date of commencement 
of Carbimazole (n) 
Yes 2 (0.6) 351 (99.4) 
Eye signs (n) 
 
 
Yes 5 (1.4) 
No 100 (28.3) 
248 (70.3) 
Neck palpation 
Enlarge thyroid 
Tenderness 
Consistency 
 
 
Yes 177 (50.1), No 41 (11.6) 
No 3 (0.9) 
Smooth- Yes 146 (41.4) 
Firm 69 (19.5) 
Nodular 5(1.4) 
 
135 (38.2) 
350 (99.2) 
133 (37.7) 
 
Ultrasound findings  Yes 11 (3.1) 
No 46 (13.0) 
NR 296 (83.9) 
 
Table 3. The relationship of age with features at presentation 
 <15 years 15-44 years >45 years Statistical 
significance (P) of 
difference between 
age groups (by x2 
test) 
Pretreatment FT4 
<12 mmol/L 
12-51 mmol/L 
>51 mmol/L 
 
1 
3 
1 
 
20 
105 
19 
 
13 
172 
8 
 
p=0.002 
Pretreatment HR 
<60 b/min 
61-80b/min 
>80b/min 
 
0 
1 
4 
 
13 
59 
74 
 
13 
172 
8 
 
p= 0.01 
Diagnosis 
GD 
 
4 
 
103 
 
82 
 
p= 0.000 
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TA 
TMG 
0 
1 
0 
45 
4 
114 
 
Table-4; Comparison of clinical and laboratory findings of those who were and were not cured 
of hyperthyroidism within 6 months of receiving a single dose 
 Cured with 1 
dose 
Not cured 
with 1 dose 
Statistical significance (p) of 
difference between the group 
that achieved cure and the 
group that did not within 6 
months (c2- test /U-test) 
 Gender 
Number (n) 
Female 
Male 
 
 
221 
28 
 
 
31 
8 
 
 
p= 0.09 (c2- test) 
Age (years) 
Median (Interquartile range) 
48 (21) 39 (16) p=0.03 (U-test) 
Pretreatment pulse rate (b/min) 
Median (Interquartile range) 
80.0 (18) 87.0 (20) p=0.502 (U-test) 
Pretreatment TSH (mIU/l)  
Median (Interquartile range) 
 
0.01 (0.01) 0.01 (0.48) p=0.06 (U-test) 
Pretreatment FT4 (pmol/l)  
Median (Interquartile range) 
 
24 (15) 27 (30.6) p=0.05 (U-test) 
% Uptake of Tc-99m pertechnatate  
Median (Interquartile range) 
5.6 (8.0) 9.9 (13.8) p=0.002 (U-test) 
Diagnosis 
GD 
TA 
TMG 
 
136 
3 
110 
 
22 
0 
17 
 
 
p=0.09 (c2- -test) 
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Chart 1 and 2. Comparison of clinical and laboratory findings of those who were and were 
not cured of hyperthyroidism within 6 months of receiving a single dose 
 
 
 
 
 
Chart 2 
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DATA SHEET 
 
Each item must be completed.  
1. If information is not available (e.g. in the clinical notes, or Nuclear medicine, NHLS and 
radiology archives), it must be entered as no record (NR). 
2. Dates must be entered as DDMMMYYYY e.g 11 Dec 2017 
3. Where permitted terms and a box are printed on the Data Sheet, mark the relevant 
box with X 
4. NS should only be used when it is printed on the Data sheet and the clinical notes 
record the accepted term but detail is insufficient; e.g. the clinical notes record the 
patient as having hypertension but do not state if it is mild, moderate or severe. 
5. For other permitted terminology check the entries on the Annotated Data Sheet  
6. If the terminology in the clinical notes or archives does not conform to a permitted 
entry, this must be discussed with the supervisor before any further data is collected. 
 
 
Demographics 
 
Folder number   
Date form completed  
Date of Diagnosis  
Date of Birth   
Gender Male ☐  Female ☐  NR ☐ 
Referred from GSH ☐  Other (specify) _________________NR ☐ 
 
 
History 
 
Comorbidities 
 
Hypertension Mild ☐  Moderate ☐  Severe ☐  NS ☐  NR ☐ 
Cardiac AF ☐  MI ☐ Angina ☐ NR ☐ 
Diabetes DM 1 ☐ DM 2 ☐ NR ☐ 
 
 
Antithyroid medication 
Drug Date Start  Date Stop 
Carbimazole NR ☐ NR ☐ 
Atenolol NR ☐ NR ☐ 
Amiodarone NR ☐ NR ☐ 
 
 
Previous radioiodine therapy? 
Yes  ☐      No ☐ 
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If yes: how many?    _______________ 
 
Date Where given 
  
  
  
 
 
 
Eye symptoms of orbithopathy           Yes  ☐  No  ☐  NR  ☐ 
 
Smoking history      Yes  ☐       No  ☐      NR ☐   
 
 
Examination 
 
Action tremors        Yes   ☐        No   ☐     NR  ☐   
 
Pulse rate (b/min)__________   regular ☐ not regular ☐  NR ☐ 
 
 
Blood Pressure (mmHg)    _________________        NR ☐ 
 
 
Eyes signs 
 NR  ☐  or  
Spontaneous retrobulbar pain  Yes ☐  No  ☐   
Pain on attempt up or down gaze Yes ☐  No  ☐   
Redness of the eyelids Yes ☐  No  ☐   
Redness of the conjunctiva Yes ☐  No  ☐   
Swelling of the eyelids Yes ☐  No  ☐   
Inflammation of the caruncle and plica Yes ☐  No  ☐   
Conjunctival oedema Yes ☐  No  ☐   
Total CAS ___/7 
 
 
Thyroid palpation 
Consistency:   Soft  ☐   Firm ☐    Nodules  ☐  NR  ☐   
Tenderness:   Tender  ☐    not tender       ☐  NR  ☐   
Smooth  ☐ NR  ☐     
Enlarged   ☐  NR  ☐  
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99m Tc- Pertechnetate thyroid scans 
No   ☐ 
If Yes 
Date____________________ 
Uptake:  
Homogeneous         Yes   ☐      No   ☐      NR  ☐   
Heterogeneous       Yes    ☐     No    ☐     NR  ☐   
Compared to salivary gland (SG)> SG  ☐    = SG   ☐   <SG   ☐   
Additional focal area(s) of increased uptake   Yes   ☐   No   ☐    NR  ☐ 
Number________      NR  ☐ 
Additional focal area(s) of decreased uptake     Yes   ☐   No   ☐    NR  ☐ 
Number_________    NR  ☐ 
Thyroid extends to sternal notch marker       Yes   ☐   No   ☐    NR  ☐ 
% Uptake_________________________       NR  ☐ 
 
 
 
Thyroid ultrasound 
No   ☐    NR  ☐ 
If Yes________________ 
Right lobe present  Yes   ☐   No   ☐    NR  ☐ 
Hyper echoic     Yes   ☐   No   ☐    NR  ☐ 
Hypo echoic     Yes   ☐   No   ☐    NR  ☐ 
Nodularity      Yes   ☐   No   ☐    NR  ☐ 
Size mm(AP x TV)_______         NR  ☐ 
 
Left lobe present  Yes   ☐   No   ☐    NR  ☐ 
Hyper echoic     Yes   ☐   No   ☐    NR  ☐ 
Hypo echoic     Yes   ☐   No   ☐    NR  ☐ 
Nodularity      Yes   ☐   No   ☐    NR  ☐ 
Size mm(AP x TV)_______         NR  ☐ 
 
Isthmus present  Yes   ☐   No   ☐    NR  ☐ 
Hyper echoic     Yes   ☐   No   ☐    NR  ☐ 
Hypo echoic     Yes   ☐   No   ☐    NR  ☐ 
Nodularity      Yes   ☐   No   ☐    NR  ☐ 
Size mm(AP x TV)_______         NR  ☐ 
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Pre-treatment Blood results  (Add rows if necessary) 
Date TSH (mIU/l) FT4 (pmol/l) FT3 (pmol/l) 
Diagnosis  (only one) 
Grave’s disease_________________☐ 
Toxic Multinodular Goiter_____☐ 
Toxic adenoma_________________☐ 
Treatment 
Date Dose (MBq) 
Activity measured at the level of epigastrium on discharge 
At 1 meter (µSv/hr)________________ 
At 2 meter (µSv/hr)________________ 
Follow up 
Follow up Bloods (add rows if necessary) 
Date TSH (mIU/l) FT4 (pmol/l) FT3 (pmol/l) 
1. 
2. 
3. 
Euthyroid state achieved 
Yes   ☐   No   ☐   Inadequate follow up    ☐ Date  ____________ 
47 
Ethics approval 
Appendix removed to avoid exposing officials signature online
